Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious and inflammatory mediated diseases. The Immuron news feed on Stock Titan aggregates company announcements, market updates and regulatory disclosures so readers can follow developments around its commercial products and clinical pipeline.
News about Immuron frequently highlights Travelan®, an over‑the‑counter immune supplement and dietary supplement based on hyper‑immune bovine antibodies that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Company updates have reported record Travelan sales in Australia and North America, marketing initiatives in retail and online channels, and clinical trial activity involving IMM‑124E, the active ingredient in Travelan, in collaboration with the Uniformed Services University.
Investors and followers can also expect coverage of pipeline milestones such as FDA interactions and clinical plans for IMM‑529, a candidate for Clostridioides difficile infection, and IMM‑986, a pre‑clinical program targeting vancomycin‑resistant enterococci. Immuron’s announcements describe pre‑clinical results, Investigational New Drug submissions and approvals, and collaborations with institutions including Naval Medical Research Command, Walter Reed Army Institute of Research and Monash University.
In addition, the news stream includes letters to shareholders, sales updates, distribution agreements such as the ProIBS® IBS product in Australia and New Zealand, and corporate communications about investor engagement initiatives. Bookmark this page to access a consolidated view of Immuron’s operational, clinical, commercial and corporate news as it is released through official channels.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced significant advancements in its research collaboration with the Naval Medical Research Center (NMRC) and CSIRO. The company signed a research agreement with CSIRO to develop a therapeutic targeting Campylobacter and ETEC for clinical evaluation. Furthermore, NMRC submitted a Pre-IND package to the FDA, anticipating comments within 30 days. A vaccination program has commenced, and two human phase II clinical trials are scheduled for 2021, focusing on protecting against campylobacteriosis and ETEC infections.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced a collaboration with the Naval Medical Research Center (NMRC) focused on developing a new oral therapeutic targeting Campylobacter and ETEC infections. A Pre-IND meeting with the FDA has been requested, paving the way for Phase II clinical trials in 2021. The trials aim to evaluate the efficacy of the therapeutic in protecting against severe campylobacteriosis and ETEC infections. However, previous study results indicated negative findings in the IMM-124E pediatric trial for Nonalcoholic Fatty Liver Disease due to a small sample size.
Summary not available.